|
|
| | SPR-741 Basic information |
| Product Name: | SPR-741 | | Synonyms: | SPR-741;NAB741;2-10-Polymyxin B1, N-acetyl-3-D-serine-;SPR741 (NAB741);SPR741TFA | | CAS: | 1179330-52-9 | | MF: | C44H73N13O13 | | MW: | 992.15 | | EINECS: | | | Product Categories: | | | Mol File: | 1179330-52-9.mol |  |
| | SPR-741 Chemical Properties |
| Boiling point | 1515.0±65.0 °C(Predicted) | | density | 1.34±0.1 g/cm3(Predicted) | | pka | 12.78±0.70(Predicted) |
| | SPR-741 Usage And Synthesis |
| Uses | SPR741 (NAB741) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741[1][2]. | | in vivo | SPR741 has the ability to permeabilize the outer membrane of Gram-negative bacteria, thus sensitizing them to hydrophobic antibiotics. SPR741 has a significantly safety profile of compared to that of polymyxin B, which suffers severe, dose-limiting nephrotoxicity in humans. In multiday rodent and nonhuman primate studies, polymyxin B exhibited nephrotoxicity at a far-lower exposure-normalized dose than SPR741[1]. | | References | [1] Corbett D, et al. Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741. Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00200-17. DOI:10.1128/AAC.00200-17
[2] Eckburg PB, et al. Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects. Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00892-19. DOI:10.1128/AAC.00892-19 |
| | SPR-741 Preparation Products And Raw materials |
|